Company profile for Actio Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Actio Biosciences is leveraging advances in precision medicine to develop new therapeutics that target shared genetics in rare and common diseases—bringing meaningful medicines from one to many. Applying its expertise in genetics, drug discovery, and data sciences, Actio seeks to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptiona...
Actio Biosciences is leveraging advances in precision medicine to develop new therapeutics that target shared genetics in rare and common diseases—bringing meaningful medicines from one to many. Applying its expertise in genetics, drug discovery, and data sciences, Actio seeks to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics. Founded in October 2021, the San Diego-based company is led by leaders in genetics and drug development and backed by top healthcare investors.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
9310 Athena Circle, Ste 100, San Diego, California 92037
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-12-05/actio-biosciences-announces-preclinical-data-highlighting-ability-of-abs-1230-to-potently-and-select

PHARMIWEB
05 Dec 2025

https://www.businesswire.com/news/home/20251124680409/en/Actio-Biosciences-to-Present-New-Preclinical-Data-for-ABS-1230-a-KCNT1-Inhibitor-for-the-Treatment-of-KCNT1-Related-Epilepsy-at-the-American-Epilepsy-Society-Annual-Meeting

BUSINESSWIRE
24 Nov 2025

https://www.pharmiweb.com/press-release/2025-09-23/actio-biosciences-announces-first-participant-dosed-in-phase-1-clinical-trial-of-abs-1230-a-kcnt1-i

PHARMAWEB
23 Sep 2025

https://www.pharmiweb.com/press-release/2025-09-10/actio-biosciences-to-participate-in-td-cowen-5th-annual-novel-mechanisms-in-neuropsychiatry-epilep

PHARMAWEB
10 Sep 2025

https://www.businesswire.com/news/home/20250730829837/en/Actio-Biosciences-Announces-U.S.-FDA-Clearance-of-Investigational-New-Drug-Application-and-Fast-Track-Designation-for-ABS-1230-a-KCNT1-Inhibitor-for-the-Treatment-of-KCNT1-Related-Epilepsy

BUSINESSWIRE
30 Jul 2025

https://www.businesswire.com/news/home/20250707260799/en/Actio-Biosciences-to-Participate-in-Evercore-Emerging-Private-Biotech-Conference

BUSINESSWIRE
07 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty